Cargando…

Improvement of Chronic Rhinosinusitis and Reduction of the Myeloperoxidase-Antineutrophil Cytoplasmic Antibody Titer in a Patient with Eosinophilic Granulomatosis with Polyangiitis by Additional Mepolizumab

A case of eosinophilic granulomatosis with polyangiitis (EGPA) in which chronic rhinosinusitis (CRS) was improved with a reduction in the myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) titer after the addition of mepolizumab is reported. A 55-year-old woman with EGPA receiving predni...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tamechika, Shin-ya, Isogai, Shuntaro, Maeda, Shinji, Naniwa, Taio, Niimi, Akio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024092/ https://www.ncbi.nlm.nih.gov/pubmed/33859858 http://dx.doi.org/10.1155/2021/5561762

Ejemplares similares

Improvement of peripheral neuropathy in a patient with antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis by additional mepolizumab
por: Kai, Yoshiro, et al.
Publicado: (2022)

Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis
por: Pradhan, Ravi Ranjan, et al.
Publicado: (2019)

High-dimensional analysis of T-cell profiling variations following belimumab treatment in systemic lupus erythematosus
por: Maeda, Shinji, et al.
Publicado: (2023)

Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis
por: Ueno, Masanobu, et al.
Publicado: (2021)

Clinical impact of proteinase 3-antineutrophil cytoplasmic antibody positivity in eosinophilic granulomatosis with polyangiitis
por: Ahn, Sung Soo, et al.
Publicado: (2022)

Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis
por: Condreay, Lynn D., et al.
Publicado: (2020)

Mepolizumab therapy improves endomyocarditis in seropositive eosinophilic granulomatosis with polyangiitis
por: Wang, Chrong-Reen, et al.
Publicado: (2022)

Concurrent Use of Mepolizumab and Rituximab for Eosinophilic Granulomatosis With Polyangiitis and Multisystem Involvement
por: Afiari, Agura, et al.
Publicado: (2020)

Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study
por: Bettiol, Alessandra, et al.
Publicado: (2021)

Successful Treatment With Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A Case Report
por: Toscano Peña, Andrés, et al.
Publicado: (2023)

Antineutrophil cytoplasmic antibody-negative granulomatosis with polyangiitis localized to the lungs
por: Ohteru, Yuichi, et al.
Publicado: (2022)

Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis
por: Vultaggio, Alessandra, et al.
Publicado: (2020)

A Pediatric Case of Relapsing Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab
por: Nara, Mizuho, et al.
Publicado: (2019)

Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab
por: Menzella, Francesco, et al.
Publicado: (2021)

Successful Treatment with Mepolizumab for Coronary Spastic Angina Associated with Eosinophilic Granulomatosis with Polyangiitis
por: Takigawa, Yuki, et al.
Publicado: (2023)

Eosinophilic Granulomatosis with Polyangiitis Presenting with Central Retinal Artery Occlusion During Treatment with Anti-interleukin-5 Receptor Monoclonal Antibody
por: Nishiyama, Hirono, et al.
Publicado: (2021)

Mepolizumab therapy in a pediatric patient with eosinophilic granulomatosis with polyangiitis associated with refractory myocarditis
por: Ulu, Kadir, et al.
Publicado: (2022)

Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype
por: Terrier, Benjamin, et al.
Publicado: (2023)

Characteristics and Disease Burden of Patients With Eosinophilic Granulomatosis With Polyangiitis Initiating Mepolizumab in the United States
por: Silver, Jared, et al.
Publicado: (2023)

Association between sinusitis and relapse and changes in the myeloperoxidase–antineutrophil cytoplasmic antibody in microscopic polyangiitis
por: Tanaka, Hiroya, et al.
Publicado: (2020)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

Anti-neutrophil Cytoplasmic Antibody-negative Eosinophilic Granulomatosis with Polyangiitis Complicated with Peripheral Neuropathy that Underwent Remission Induction with Mepolizumab Monotherapy
por: Nishihara, Masahiro, et al.
Publicado: (2023)

Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis
por: Masumoto, Nami, et al.
Publicado: (2023)

Myeloperoxidase-Antineutrophil Cytoplasmic Antibody-Negative Microscopic Polyangiitis with Pulmonary Haemorrhage and IgA Nephropathy
por: Endo, Yuichiro, et al.
Publicado: (2011)

The Successful Treatment of Myeloperoxidase Antineutrophil Cytoplasmic Antibody-positive Hypertrophic Pachymeningitis in Patients with the Limited Form of Granulomatosis with Polyangiitis Using Methotrexate: Two Case Reports
por: Kaieda, Shinjiro, et al.
Publicado: (2017)

Limited Antineutrophil Cytoplasmic Antibodies (ANCA)-Negative Granulomatosis With Polyangiitis: Successful Response to Rituximab
por: Andrade, Maria Margarida, et al.
Publicado: (2023)

Myeloperoxidase-antineutrophil Cytoplasmic Antibodies with Cytoplasmic Fluorescence Pattern
por: Chhabra, Seema, et al.
Publicado: (2010)

Eosinophilic Granulomatosis with Polyangiitis
por: Shukla, Ratnakar, et al.
Publicado: (2022)

A Case of Effective Mepolizumab Induction Therapy for Severe Eosinophilic Granulomatosis with Polyangiitis Diagnosed by Eosinophilic Cholecystitis and Interstitial Nephritis
por: Hattori, Keita, et al.
Publicado: (2021)

Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study
por: Ueno, Masanobu, et al.
Publicado: (2022)

Effective treatment with mepolizumab in a patient with severe eosinophilic granulomatosis with polyangiitis complicated with small intestine perforation
por: Sato, Mari, et al.
Publicado: (2023)

The visualization of hypertrophic pachymeningitis in antineutrophil cytoplasmic antibody-associated granulomatosis with polyangiitis on contrast-enhanced FLAIR
por: Yoshikawa, Satoshi, et al.
Publicado: (2023)

COVID-19 and eosinophilic granulomatosis with polyangiitis or COVID-19 mimicking eosinophilic granulomatosis with polyangiitis?
por: Özdemir, Bahar, et al.
Publicado: (2021)

Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy
por: Faverio, Paola, et al.
Publicado: (2018)

Exacerbation of Eosinophilic Granulomatosis With Polyangiitis After Administering Dupilumab for Severe Asthma and Eosinophilic Rhinosinusitis With Nasal Polyposis
por: Tanaka, Shunya, et al.
Publicado: (2022)

Eosinophilic Granulomatosis with Polyangiitis: An Overview
por: Gioffredi, Andrea, et al.
Publicado: (2014)

Prevasculitic Eosinophilic Granulomatosis With Polyangiitis
por: Burtson, Kathryn M, et al.
Publicado: (2021)

Eosinophilic Variant of Granulomatosis With Polyangiitis
por: Fernandes, Rui L, et al.
Publicado: (2023)

Circulating Th17.1 cells as candidate for the prediction of therapeutic response to abatacept in patients with rheumatoid arthritis: An exploratory research
por: Maeda, Shinji, et al.
Publicado: (2019)

Correction to: COVID-19 and eosinophilic granulomatosis with polyangiitis or COVID-19 mimicking eosinophilic granulomatosis with polyangiitis?
por: Özdemir, Bahar, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v7mebl7v7uglj18rlfiaicb08d